• It is the responsibility of both parties (the previous manufacturer and new manufacturer) to complete an NDC Transfer form in its entirety and submit it to dha.ncr.healthcare-ops.mbx.ufvarr-requests@health.mil. The form must contain the signatures of both parties. Once the TRICARE Retail Refund Team (TRRT) receives, reviews, and approves the form, billing can be updated. Please note that if the form is submitted with transfer dates in a previous quarter, the transfer will be reflected in the upcoming billing quarter.
• If a pharmaceutical agent being transferred has an active ADP Agreement in place, contact DHA Contracting or the DHA Industry Technical Liaison via Email.

It is not necessary to notify the TRRP. A drug deemed obsolete does not necessarily mean that the drug is expired, it means an NDC is discontinued, no longer marketed, no longer produced, no longer distributed, or otherwise made unavailable to the marketplace. It is normal for NDCs to be dispensed after the obsolete date, as pharmacies may still have stock on the shelf after that date. If DHA provides utilization data for program eligible covered drugs, a refund is owed.

If an NDC is reported to the TRRT with a positive minimum refund, it is a covered drug under 38 U.S.C. 8126 of the final rule and eligible for the TRICARE Retail Refund Program. A refund will be owed for covered drugs dispensed through pharmacies identified as part of the TRICARE Retail Network, which includes long term care facilities, specialty pharmacies, and pharmacies inside physician offices or hospitals. In the event that an NDC appears to be incorrectly reported to TRICARE as a covered drug, please contact your POC at the Department of Veterans Affairs. The manufacturer may also submit disputes for these claims (please see the Dispute Submission process in the TRICARE Retail Refund Program Process & Procedures Guide) so that proper credit can be given in the event that the disputes are accepted.

Although Section 703 Compliant, there are many reasons as to why a drug may not be covered under TRICARE formulary. All formulary questions should be directed to the DHA Industry Technical Liaison via email.

All ADP Agreements for drugs belonging to drug classes reviewed in Pharmaceutical & Therapeutics Committee Meetings will be terminated upon the effective dates determined within the review of each class, regardless of formulary standing. However, if a drug is designated non-formulary per the P&T Committee, a bid that may have been submitted for consideration will not be accepted. ADP Agreements to be terminated will be done so with a termination date determined within each class (not the signing of the minutes unless otherwise indicated). Please refer to the P&T Committee Meeting Minutes for more information.

• If an NDC is not included on an ADP Agreement and the pharmaceutical agent is the same for the NDC(s) for which an ADP Agreement is in place, it will be referred to DHA Contracting for review and decision.
• Typically, WAC ADP Agreements will include drugs that are not Covered Drugs, such as diabetes testing supplies. If the NDC is not included on the WAC ADP Agreement for a non-Covered Drug, it will not be billed under WAC, ADP, or SDP. If the NDC of the pharmaceutical agent on the ADP Agreement is a Covered Drug, then it will be billed ADP (FCP or WAC based on the ADP Agreement in place)
• Please refer further questions to DHA Contracting or the DHA Industry Technical Liaison via Email.

• Based upon analysis of the utilization data used in prior billings, TRICARE determined it must re-bill through 4th Quarter of Calendar Year 2011. TRICARE does not anticipate re-billing any additional quarters will be necessary.
• Nevertheless, if there are significant changes to manufacturer utilization data or refund calculations, TRICARE may be required to re-bill additional quarters.